Filana Therapeutics的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 4 条
2024
研究欺诈和证券欺诈诉讼
司法部指控顾问黄浩彦涉嫌与simufilam研究和NIH拨款申请相关的伪造行为。SEC另行指控公司、黄浩彦、Remi Barbier和Lindsay Burns涉嫌在试验数据和项目利益方面作出误导性陈述和遗漏。SEC事项在不承认不当行为的情况下和解,而司法部后来撤销了对黄浩彦的案件。
2022
Cassava Sciences因涉嫌数据操纵及投资者陈述被起诉
提起诉讼
原告Patricia Matranga起诉Cassava Sciences董事会及高层管理人员,指控其违反信托义务。诉状称,被告促使公司向FDA提交经过操纵的数据,并就simufilam向投资者作出重大虚假及误导性陈述。
来源摘录
On Tuesday, plaintiff Patricia Matranga filed a suit against the board of directors and upper management of Cassava Sciences, Inc in the Western District of Texas.
The complaint states that “the individual defendants caused the company to submit manipulated data to the U.S Food and Drug Administration and made, or caused the company to make, materially false and misleading statements to the investing public.”
On Tuesday a case was filed in the Western District of Texas by Manhoar Rao, as a proposed class action, against Cassava Sciences Inc., Remo Barbier, and Eric Schoen. The case is regarding violations of federal securities law regarding disclosures made regarding the Alzheimer’s treatment simufilam.
2021
2021
SEC据报道调查Cassava Sciences研究相关指控
调查
报道指出,美国证券交易委员会正在调查有关Cassava Sciences操纵研究结果的指控。Cassava称其正在配合要求提供公司信息和文件的政府机构。
品牌回应
持续披露 — Cassava Sciences
Cassava, based in Austin, Texas, revealed in a regulatory filing on Monday that it is 'cooperating' with 'certain government agencies' that have asked it to provide corporate information and documents.
来源摘录
Cassava, based in Austin, Texas, revealed in a regulatory filing on Monday that it is 'cooperating' with 'certain government agencies' that have asked it to provide corporate information and documents.
The US Securities and Exchange Commission is reportedly investigating claims that Alzheimer's drug developer Cassava Sciences manipulated research results using Photoshop to alter images in a scientific paper.